PG 102 - ViroMed

Drug Profile

PG 102 - ViroMed

Alternative Names: PG102-ViroMed

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ViroMed Co Ltd
  • Developer SBI Biotech; ViroMed
  • Class Plant allergy immunotherapies
  • Mechanism of Action Helper-inducer T-lymphocyte inhibitors; IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic contact dermatitis
  • No development reported Allergic rhinitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-rhinitis in Japan
  • 17 Jun 2015 PG 102 is still in phase-II development for Allergic diseases in South Korea
  • 17 Jun 2010 Phase-II clinical trials in Allergic contact dermatitis in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top